News & Analysis as of

Pharmaceutical Industry Forex

Robins Kaplan LLP

Financial Daily Dose 7.29.2019 | Top Story: Pfizer and Mylan Join Forces to Create Generics Powerhouse

Robins Kaplan LLP on

Drug giants Pfizer and Mylan have inked a deal that will merge the former’s off-patent drugs with the latter’s generics business, a tie-up that creates a mammoth global seller of lower-priced medicines....more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

OxyContin maker Purdue Pharm is prepping for a possible bankruptcy filing “as it seeks to contain liability from hundreds of lawsuits alleging it fueled the nation’s opioid epidemic.” Officially, the company went on the...more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

The US and South Korea have announced a deal to renegotiate their trade pact, with “South agreeing to reduce its steel exports and open its market to American cares” in exchange for an exemption from the White House’s steel...more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

Swiss pharma giant Novartis has issued a $3.9 billion cash bid to buy Advanced Accelerator Applications, a French company [and spinoff of the organization in charge of the Large Hadron Collider] known for producing...more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

The Peltz/P&G drama continues, with the company suggesting that Trian has lost its bid for a Board seat and the fund arguing that it disagrees with the company’s counting of the ballots....more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

Drugmaker Gilead has kickstarted a largely quiet period for big pharma deals with the announcement that it’s acquiring Kite for about $11.9 billion. Kite Pharma’s best known for its emerging cancer treatments that focus on...more

Robins Kaplan LLP

Your Daily Dose of Financial News

Robins Kaplan LLP on

Mylan will pay $465 million to federal authorities to resolve claims that it overcharged the Medicaid program by millions for its EpiPen products. Though large, the figure represents about a third of the estimated...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 5.23.16

Robins Kaplan LLP on

We’ve got numbers for Bayer’s unsolicited bid to buy Monsanto—a cash offer of $62 billion, representing a 37% premium on Monsanto’s May 9 closing price...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 3.16.16

Robins Kaplan LLP on

Chair Yellen will report on the Fed’s latest meeting at 2pm EDT today. Thanks to the Journal, we’ve got 5 Things to Watch when she does – WSJ... All is not well at Valeant, the struggling drug maker whose stock dropped...more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide